Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159978 | 1.00 | TSHR (0.49) | TSHRNPSR1BLMFOLH1CYP3A4 | |
| Normetanephrine SCHEMBL4220340 | 0.87 | NFKB1 (0.63) | TSHRNPSR1BLMFOLH1CYP3A4 | |
| Acetic Acid SCHEMBL11500096 | 0.86 | HTT (0.48) | TSHRNPSR1BLMFOLH1CYP3A4 | |
| SCHEMBL3129051 | 0.84 | FPR2 (0.60) | TSHRGAAALDH1A1KMT2AALOX15 | |
| SCHEMBL5101470 | 0.83 | LMNA (0.55) | TSHRNPSR1BLMFOLH1GAA | |
| SCHEMBL300286 | 0.82 | ERCC1 (0.46) | TSHRNPSR1BLMGAANFKB1 | |
| SCHEMBL300287 | 0.82 | ERCC1 (0.46) | TSHRNPSR1BLMGAANFKB1 | |
| SCHEMBL9413247 | 0.81 | TSHR (0.53) | TSHRNPSR1BLMFOLH1GAA | |
| SCHEMBL9069063 | 0.81 | TSHR (0.53) | TSHRNPSR1BLMFOLH1GAA | |
| Hydrochloric Acid SCHEMBL15266596 | 0.80 | ERCC1 (0.45) | TSHRNPSR1BLMGAANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221552-A1 | Methods for the Treatment of ADHD and Related Disorders | THE MCLEAN HOSPITAL CORPORATION (US) | 2009-09-03 | — | — | US | claimed |
| WO-2007100777-A2 | METHODS FOR THE TREATMENT OF ADHD AND RELATED DISORDERS | THE MCLEAN HOSPITAL CORPORATION (US) | 2007-09-07 | — | — | WO | claimed |
| US-6403645-B2 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-06-11 | — | — | US | claimed |
| US-20020013312-A1 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-01-31 | — | — | US | claimed |
| CN-118834920-A | Method for synthesizing tanshinol by using chemical enzyme cascade system | 南京工业大学 | 2024-10-25 | — | — | CN | disclosed |
| WO-2009134877-A2 | THERAPEUTICS FOR TREATMENT RESISTANT MENTAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090221552-A1 | Methods for the Treatment of ADHD and Related Disorders | THE MCLEAN HOSPITAL CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2007100777-A2 | METHODS FOR THE TREATMENT OF ADHD AND RELATED DISORDERS | THE MCLEAN HOSPITAL CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070116643-A1 | Novel aryloxypropanamines | CONCERT PHARMACEUTICALS INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007005644-A2 | NOVEL ARYLOXYPROPANAMINES | CONCERT PHARMACEUTICALS INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221552-A1 | Methods for the Treatment of ADHD and Related Disorders | SLC6A3, SLC6A2, SLC6A4 | TSHR 2273/4885NPSR1 859/4885BLM 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.